Temsirolimus is the standard of care for treatment naive poor risk metastatic kidney cancer with better overall survival than either IFN or combination therapy

Temsirolimus is the standard of care for treatment naive poor risk metastatic kidney cancer with better overall survival than either IFN or combination therapy

In this study 626 patients were randomized to either temsirolimus an mTOR inhibitor or IFN or a combination of the two. Temsirolimus was a 25 mg weekly 30 minute intravenous dose. Temsirolimus side effects were high blood sugars, rash, peripheral oedema, high lipids. The temsirolimus alone group had the highest progression free survival rate and overall survival rate of 10.9 months (v 7.3 IFN and 8.4 combination). Patients had to have at least 3 of 6 poor risk factors (LDH >1.5 upper limit, anemia, calcium > 2.5 mmol/l, recurrence time

Start typing and press Enter to search